Clinical Trials Logo

Clinical Trial Summary

Chronic Migraine (CM) and High Frequency Episodic Migraine (HFEM) without Aura affect adolescents' lives in terms of reduced health, reduced ability to perform daily chores and reduced quality of life. The use of pharmacological prophylaxis in these patients warrants caution, whereas the use of behavioral treatments is gaining support in literature. The main aim of MINDKIDS trial is to test the effect of a seven weekly group sessions of guided mindfulness-based meditation program on 12-month headache frequency reduction, medications intake, disability, anxiety, depression, catastrophizing, and caregivers' burden. This is a single-arm study. All patients will participate to seven weekly guided sessions (60 minutes each) of guided mindfulness meditation, which is aimed to teach and make direct practice with skills intended to enhance sustained, non-judgmental present moment awareness. The intervention's main topics are: posture education; breath use and control; guided body scan; work with sounds; tension release; guided imagery; decentralization of thoughts. Each session is conducted by a neurologist and a psychologist expert in mindfulness practice. During the sessions, patients are asked to close their eyes and focus their attention on the breathing so that they can concentrate on the present moment and on all the sensations. Patients were educated to promote a healthy lifestyle: regular physical activity, avoiding skipping meals, hydration, maintain a regular sleep/wake pattern at least 7-8 hours per night.


Clinical Trial Description

Background and significance Adolescents with Chronic Migraine (CM) and High Frequency Episodic Migraine (HFEM) without Aura, characterized by 15+ and 9-14 days with headache respectively, pose a relevant burden on adolescents' health, quality of life, as well as on their ability to perform school and leisure time activity. In addition to this, tackling such health conditions in adolescence might be of great importance to reduce the likelihood of a transition to adulthood with CM and medication overuse headache. In this category of patients, it is suggested to avoid prescribing pharmacological prophylaxis, in favour of non-pharmacological approaches, such as nutraceuticals or behavioural techniques. Behavioural approaches are considered helpful for younger patients with HFEM and CM to manage pain and to reduce the number of analgesics and the use preventive medications. Mindfulness, in particular, has been applied in several clinical experiences in adults with pain and migraine with encouraging results, with long term benefit similar to that obtained from pharmacological prophylaxis. The clinical use of mindfulness in adolescents is limited to few experiences, however some results in this group of patients are encouraging. A non-randomized pilot study demonstrated acceptability and feasibility of a mindfulness-based treatment for adolescents with recurrent headaches (1). Another study demonstrated how mindfulness was able to reduce depression in children and adolescents suffering from migraine associated with depression (2). A third small pilot study (3) showed positive results with the use of mindfulness in young patients with headache. Taken as a whole, these studies seem to point out that mindfulness-based protocol for adolescents with CM or HFEM are feasible and acceptable. What has to be better addressed is the effect of such a kind of treatment: available information, however, enable us to hypothesize that reduction in headache frequency from baseline over a 12-months period could be higher or equal to 50%. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04968093
Study type Interventional
Source Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Contact
Status Completed
Phase N/A
Start date January 2016
Completion date January 2021

See also
  Status Clinical Trial Phase
Completed NCT02253004 - Induction of Migraine Aura With Cilostazol Phase 0
Recruiting NCT02202486 - Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI N/A
Completed NCT00123201 - Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache Phase 2
Completed NCT04406649 - A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine Phase 3
Completed NCT03874832 - A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects Phase 1
Recruiting NCT05565001 - The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. N/A
Recruiting NCT05416476 - Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine Phase 3
Active, not recruiting NCT02906085 - Endothelin-1 as a Potential Trigger of Migraine Aura N/A
Recruiting NCT00893594 - Efficacy of Sumatriptan With Naprosyn in Migraine With Aura N/A
Completed NCT01388699 - Migraine and Endothelial Dysfunction
Completed NCT00534560 - Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Phase 2
Terminated NCT04936061 - Transnasal Cooling for Migraine N/A
Recruiting NCT05281770 - Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
Not yet recruiting NCT04063540 - Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura Phase 2
Completed NCT03472417 - Partial Rebreathing in the Treatment of Migraine With Aura N/A
Completed NCT00334178 - Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine Phase 3
Recruiting NCT06051604 - Mi-Helper Transnasal Cooling for Acute Treatment of Migraine N/A
Completed NCT03472378 - Can DFN-15 Terminate Migraine With Allodynia? Phase 2
Recruiting NCT05211154 - Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine Phase 4
Completed NCT02708797 - Brainstem Grey Matter and Cerebral Autoregulation in Migraine With Aura. N/A